"Genetic Vectors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
| Descriptor ID |
D005822
|
| MeSH Number(s) |
G05.360.337
|
| Concept/Terms |
Genetic Vectors- Genetic Vectors
- Genetic Vector
- Vector, Genetic
- Vectors, Genetic
Shuttle Vectors- Shuttle Vectors
- Shuttle Vector
- Vector, Shuttle
- Vectors, Shuttle
Cloning Vectors- Cloning Vectors
- Cloning Vector
- Vector, Cloning
- Vectors, Cloning
|
Below are MeSH descriptors whose meaning is more general than "Genetic Vectors".
Below are MeSH descriptors whose meaning is more specific than "Genetic Vectors".
This graph shows the total number of publications written about "Genetic Vectors" by people in this website by year, and whether "Genetic Vectors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 2 | 5 | 7 |
| 2008 | 1 | 3 | 4 |
| 2009 | 1 | 5 | 6 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 5 | 7 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genetic Vectors" by people in Profiles.
-
Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9. Gene Ther. 2022 06; 29(6):390-397.
-
Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiol Dis. 2021 01; 148:105184.
-
Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
-
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res. 2019 10 01; 25(19):5808-5817.
-
Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier? Mov Disord. 2019 09; 34(9):1279-1282.
-
Disease Modification Through Trophic Factor Delivery. Methods Mol Biol. 2018; 1780:525-547.
-
First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. J Immunother. 2017 10; 40(8):302-306.
-
Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun. 2017 06 16; 5(1):47.
-
AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned? Methods Mol Biol. 2016; 1382:485-90.
-
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.